Go and Doyle address important clinical questions based on our recent study showing that multiple myeloma (MM) is universally preceded by a prolonged premalignant stage. 1 Although the questions raised are not directly related to our paper, which focused primarily on a key biologic question, they are commonly encountered in clinical practice and worth discussing.
Routine screening for MGUS is not indicated. Therefore, almost all individuals diagnosed with MGUS represent incidental cases diagnosed when physicians order a serum protein electrophoresis and/or immunofixation as part of the workup of several common symptoms and laboratory abnormalities. Once diagnosed, patients must be appropriately counseled that MGUS is a premalignant entity with a relatively low risk of progression to MM or related malignancies. In fact, MGUS cases with small (Ͻ 1.5 g/dL) IgG monoclonal (M)-proteins and with a normal serum free light chain ratio, represent approximately 40% of all cases, and have only a 2% lifetime probability of developing MM or related malignancies. We have previously recommended that such MGUS cases may not need annual follow-up, but can rather be followed if symptoms suggestive of MM or related disorders occur. 2 In contrast, we feel that MGUS cases with higher risk may benefit from annual follow-up of the M-protein in addition to their usual medical care. Although the value of this is not proven, the test is simple, and, in our opinion, worth doing considering that MM can present with devastating bone complications that may be preventable in some patients if a significant rise in the M-protein is detected in time.
Although, for the individual patient, it is currently not possible to predict whether the underlying MGUS will remain benign or transform to MM, from a population standpoint the significance of MGUS has been well characterized. Several studies have determined the risk of transformation of MGUS patients over time, 3, 4 and identified risk factors for such transformation. 2, 5 In addition to malignant transformation, MGUS patients also have a higher risk of several pathologic conditions, including fractures 6 and deep vein thrombosis. 7 Furthermore, recent data suggest that MGUS cases (compared with the general population) have a significantly reduced life expectancy and an excess risk of dying from bacterial infections and heart, liver, and renal diseases, 8 although this may be related to the various underlying medical conditions that led to the detection of the MGUS. Additional clinical and epidemiologic studies of MGUS are needed.
Our recent observation that MM is universally preceded by a prolonged premalignant stage, with up to 75% of MM patients having detectable M-protein 8 or more years before diagnosis of the malignancy, fills a key gap in the present literature on myelomagenesis. 1 Simultaneously, we found that stable M-protein or free light chain levels do not exclude the development of MM development. 1 Weiss et al reported similar findings in their study based on samples from a US military serum repository. 9 Thus, as pointed out in our prospective study, 1 important tasks for the future are to develop individualized follow-up and intervention approaches for MGUS patients. We are undertaking further clinical and laboratory studies to provide insights on the pathogenesis of MGUS, racial disparities in the incidence of MGUS and MM, and to understand the cellular and microenvironmental events that are result in the transformation of MGUS to MM or related malignancies. Clinical trials investigating preventive therapy for high-risk patients with MGUS are also under way.
To the editor:
Does HUMARA assay for assessment of clonal hematopoiesis have shortcomings?
Determination of clonality based on assays of inactivation of genes encoded on the X chromosome has provided important insights into the origins of neoplastic diseases. The following characteristics make a clonality assay informative: (1) the gene being assayed must undergo X inactivation such that only one allele is expressed in a somatic cell in females; (2) the gene of interest should be sufficiently polymorphic so as to be informative in a reasonably high proportion of the population; (3) the assay should be quantitative because skewing of X inactivation is a normal biologic process determined by the proportion of cells with an active paternal or maternal X chromosome that occurs randomly during embryogenesis; and (4) the assay should be sufficiently robust so that accurate determinations applicable to a variety of tissues can be made at various X chromosome loci. 1 The human androgen receptor gene (HUMARA) assay has been widely used to establish clonality; however, we and others had concerns that the assay might produce spurious results. 1,2 Several groups have previously reported that the HUMARA assay is not suitable for elderly females since monoallelic Xchromosome methylation or extreme skewing is detected in a significant proportion of them, suggesting clonal or oligoclonal hematopoiesis. [3] [4] [5] [6] The conclusion that hematopoiesis is monoclonal in approximately one-third of healthy elderly women seems biologically untenable. The HUMARA assay is based on indirect determination of the methylated state of 2 CCGG sites neighboring a polymorphic CAG repeat, by the HpaII methylation sensitive restriction endonuclease, followed by amplification of the undigested methylated DNA by PCR and size fractionation on a capillary electrophoresis system. Inactive Xchromosome allelic ratios are estimated using the area under the peak of PCR amplified size fractionated alleles, which vary, based on the number of CAG repeats. Because of the baroque nature of the HUMARA assay that might result in artifactual findings, we have developed an unambiguous direct assay to measure allele-specific expression of 5 genes, subject to X-inactivation, based on quantization of transcribed single nucleotide exonic polymorphisms. 1, 2, 7, 8 In our recent paper in the October 15, 2008 issue of Blood, 9 we studied 40 healthy elderly female volunteers (range, 65-92 years; mean, 81.3 years; median, 82 years). These women were carefully screened for a lack of any acute or chronic disease and had normal blood counts. We analyzed their peripheral blood cells using a novel quantitative transcriptional assay (qTCA) based on determination of allele-specific ratios of the 5 X-chromosome genes. As reported, 9 these assays distinguish each polymorphic SNP allele by more than 13 PCR cycles. 9, 10 We did not find any indication of clonal or oligoclonal hematopoiesis, and transcribed allelic ratios were comparable with those of younger women. However, when we analyzed granulocyte DNA from the same subjects using the HUMARA assay, we found a significant proportion with monoallelic methylation of the HUMARA locus, yet no evidence of skewed X-inactivation as determined by our novel qTCA. 9 These data were recently challenged by Busque and colleagues, 11 who claim to find complete concordance between methylation of the HUMARA locus and X-chromosome allelic usage. Notably, the mean age of their elderly cohort was only 71 years. We believe these contradictory results may be explained as follows:
(1) The "suppressive PCR" assay described in Busque's paper does not appear to be the same, since they did not perform the qTCA as described in our paper. 9 The PCR reagents and conditions as described by Busque et al (platinum-Taq-SYBR-super-mix and a low annealing temperature 45°C, primer Tm ϭ 60°C) result in increased amplification of the wrong allele and thus poor allelic discrimination, and decreased specificity. 12 The number of PCR cycles required to discriminate both IDS alleles using their
